# A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Source: https://onco.cc/trials/nct06962787/  
OnCo record `nct06962787` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Axitinib, Lenvatinib and Pembrolizumab in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer is a phase 2 interventional study registered as NCT06962787 by Sichuan Baili Pharmaceutical Co., Ltd., with 260 participants planned, started 2025-07-28 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1, Axitinib, Lenvatinib and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06962787
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 in Combination With Tyrosine Kinase Inhibitor (TKI) With or Without Pembrolizumab (BL-B01D1+TKI±Pembrolizumab) in Patients With Locally Advanced or Metastatic Renal Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT06962787: https://clinicaltrials.gov/study/NCT06962787

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Axitinib](https://onco.cc/drugs/axitinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06962787.json